Article (Scientific journals)
Le medicament du mois. Sitagliptine (Januvia): incretinopotentiateur indique comme insulinosecretagogue dans le traitement du diabete de type 2.
Scheen, André; Van Gaal, L. F.
2008In Revue Médicale de Liège, 63 (2), p. 105-9
Peer reviewed
 

Files


Full Text
200802_11.pdf
Publisher postprint (506.58 kB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Belgium; Diabetes Mellitus, Type 2/drug therapy; Glucagon-Like Peptide 1/drug effects/metabolism; Humans; Hypoglycemic Agents/adverse effects/pharmacokinetics/therapeutic use; Incretins/metabolism; Insulin/secretion; Insurance, Health, Reimbursement; Insurance, Pharmaceutical Services; Pyrazines/adverse effects/pharmacokinetics/therapeutic use; Triazoles/adverse effects/pharmacokinetics/therapeutic use
Abstract :
[en] Sitagliptin (Januvia) is the first selective antagonist of dipeptidylpeptidase-4, an enzyme that degrades glucagon-like peptide-1 (GLP-1). This hormone is mainly secreted by ileal L cells and this secretion is abnormally low in patients with type 2 diabetes. Sitagliptin increases post-meal insulin secretion ("incretin effect) by enhancing the postprandial GLP-1 response ("incretin enhancer"), in a glucose-dependent manner. It improves glycaemic control (HbA1c) in type 2 diabetic patients treated by diet alone, by metformin, by sulfonylurea, by glitazone or by a metformin-sufonylurea combined therapy. The glucose-lowering effect is similar to that of glipizide, but with the advantage of no weight gain and no hypoglycaemic episodes. The tolerance to sitagliptin is excellent. Treatment is simple, with 100 mg once daily, without need of titration or home blood glucose monitoring. In Belgium, sitagliptin is currently reimbursed in patients with type 2 diabetes not adequately controlled with diet and metformin monotherapy.
Disciplines :
Endocrinology, metabolism & nutrition
Author, co-author :
Scheen, André  ;  Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale
Van Gaal, L. F.;  Hôpital universitaire d’Anvers. > Département de Diabétologie, Métabolisme et Nutrition clinique
Language :
French
Title :
Le medicament du mois. Sitagliptine (Januvia): incretinopotentiateur indique comme insulinosecretagogue dans le traitement du diabete de type 2.
Alternative titles :
[en] Sitagliptine (Januvia): incretin enhancer potentiating insulin secretion for the treatment of type 2 diabetes
Publication date :
2008
Journal title :
Revue Médicale de Liège
ISSN :
0370-629X
eISSN :
2566-1566
Publisher :
Université de Liège. Revue Médicale de Liège, Liège, Belgium
Volume :
63
Issue :
2
Pages :
105-9
Peer reviewed :
Peer reviewed
Available on ORBi :
since 14 January 2009

Statistics


Number of views
723 (2 by ULiège)
Number of downloads
1375 (1 by ULiège)

Scopus citations®
 
23
Scopus citations®
without self-citations
8

Bibliography


Similar publications



Contact ORBi